Diseases – Page 11
-
ArticleUnlocking the power of stem cell therapy
In this Q&A, founder of Scheer Medical Wellness Dr Alexander Scheer shares his insights, discussing the current challenges in stem cell therapy and how these can be addressed, the advancements in delivery techniques, and stem cells’ overall potential in regenerative medicine.
-
ArticleInvestigating the intratumoural microbiome in young-onset CRC patients
New insights about young-onset CRC tumour-related bacteria could lead to new diagnostic markers and therapeutic targets.
-
ArticleSARS-CoV-2 viral peptide fragments cause serious inflammatory response
In this Q&A, Dr Gerard Wong elucidates the inflammatory capacity of fragmented viral components from the perspective of supramolecular self-organisation.
-
ArticleThe great prostate debate: innovations in prostate cancer screening
While blood tests measuring prostate-specific antigen (PSA) levels have been a primary screening tool, their limitations in specificity have led to challenges such as overdiagnosis and overtreatment. Cleveland Diagnostics is pioneering an alternative approach with the IsoPSA test, focusing on assessing the structure of the PSA protein rather than its ...
-
ArticleHow 3D human tissue models are transforming drug discovery
In this Q&A, Keith Murphy, CEO of Organovo, discusses how the shift from animal models to 3D human tissues can transform the preclinical space. Among his many insights, he details the limitations of animal models, how Organovo’s 3D human tissue models facilitate a deeper understanding of genetic expression within specific ...
-
ArticleSARS-CoV-2: advancing the production of the ACE2 protein
Producing functional human ACE2 protein in mouse cells provides a new way to study the receptor used by the SARS-CoV-2 spike protein.
-
ArticleTherapeutic peptide developed for triple-negative breast cancer
Scientists demonstrate how disrupting the Cx26 molecular complex in triple-negative breast cancer cells slowed tumour growth.
-
ArticleUsing proteomics to overcome glioblastoma resistance
Using an AI algorithm to predict glioblastoma’s most active kinase, researchers hope for a next-generation precision therapy targeting resistant cancers.
-
ArticleTransforming cancer treatment for greatest impact
In this Q&A, Dr Lev Becker, Associate Professor, University of Chicago and Cofounder of Onchilles Pharma, reveals how his company is directing research into neutrophil biology to the advantage of cancer patients that need it most.
-
ArticleDeveloping in-vivo chimeric lungs with pluripotent stem cells
Reverse-blastocyst complementation elucidates the conditions required to form lungs in rat-mouse chimeric models.
-
ArticleHow AI is accelerating the future of precision medicine
Dr Ketan Patel, Clarivate, shares his insights about the use of Real-World Data and genomic biomarker data and discusses how researchers can use these to better detect and diagnose diseases.
-
ArticleGrowth hormone’s influence on neuropsychiatric disorders
The discovery of a mechanism involving anxiolytic effects of GH may lead to the development of new classes of anxiolytic drugs.
-
ArticleA Guide to DNA Damage Response and Innate Immunity
In this guide, we provide an overview of the DDR and innate immune pathway and describe Transcreener Assays and Assay Systems for key targets.
-
ArticleBiological robots: a new therapeutic tool
Anthrobots derived from human tracheal cells could perform therapeutic work without initiating an immune response.
-
ArticleAllosteric control sites in KRAS protein found
The first complete control map for any protein has been made for KRAS, and four potential drug targets have been discovered.
-
ArticleThe promise of nanobodies to neutralise the human norovirus
A new discovery about the dynamic structure of norovirus particles has implications for vaccine development.
-
ArticleNew biomarkers found for diabetic kidney disease
Biomarkers found through urinary and exosome proteome profiling have potential for diagnosis and disease monitoring.
-
ArticleNot all neoantigens are created equal
Founder and CSO of Achilles Therapeutics Dr Sergio Quezada reveals how the landmark TRACERx study has gleaned key insights that could make the difference between success and failure in immunotherapy treatment.
-
ArticleThe potential of CD24 in cancer immunotherapy
Cofounder & Chief Scientific Officer of Pheast Therapeutics, Dr Roy Maute, reveals his company’s promising drug candidate and explains why they have focused on their chosen target.
-
ArticleDrug Target Review - Issue 4 2023
A new Drug Target Review issue is now ready to download! This issue features articles on CRISPR, personalised medicine and screening.